WT1 2-Log Reduction After Induction Therapy Predicts Outcomes in Acute Myeloid Leukemia Patients
Year: 2026
Type: article
Study design: Observational Study
Abstract: The WT1 gene is overexpressed in 80–90% of acute myeloid leukemia (AML) cases, and its expression has been associated with several molecular alterations, i.e., FLT3 and NPM1 mutations, representing a complementary marker for prognostic assessment and measurable residual disease (MRD) monitoring. However, its clinical and prognostic significance in AML has not yet been fully clarified. We retrospectively evaluated WT1 expression at diagnosis and its possible value in MRD assessment in AML patients treated with intensive chemotherapy at the Hematology Units of Siena and Ravenna. WT1 transcript levels were quantified in bone marrow samples at diagnosis and post-induction therapy by standardized RT-qPCR. This study involved 120 AML patients; according to ELN 2022, 44 (36.7%) patients were classified as adverse, 50 (41.7%) as intermediate, and 26 (21.7%) as favorable risk. Median WT1 expression was 4559 copies/104 ABL1 at diagnosis and 122 copies/104 ABL1 after induction therapy. A post-induction WT1 reduction of >2 logs was significantly associated with improved overall survival (OS) and event-free survival, as well as prolonged time to relapse. Combining WT1 reduction with FLT3 status further stratified OS, with the poorest outcome observed in patients with <2-log reduction and persistent FLT3 positivity. Changes in WT1 levels, especially a >2-log reduction after induction therapy, could provide complementary MRD information in AML, including for patients lacking leukemia-specific molecular targets.
Authors: Mariachiara Cuccaro(Investigation, Writing – original draft), Anna Sicuranza(Conceptualization, Methodology, Writing – original draft), Adele Santoni(Conceptualization, Investigation), Giovanni Marconi(Conceptualization, Investigation), Margherita Malchiodi(Investigation), Michela Rondoni(Conceptualization, Investigation, Writing – review & editing), Alessandra Cartocci(Data curation, Formal analysis), Karim Palombo(Data curation, Investigation), Sara Monti(Investigation), Cristina Marzano(Methodology), Camilla Turriziani(Methodology), Teresa Miracapillo(Methodology), Beatrice Anna Zannetti(Investigation), Serena Rocchi(Investigation), Francesco Lanza(Supervision, Writing – review & editing), Monica Bocchia(Conceptualization, Supervision, Writing – review & editing)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7234148404
